Stryker is acquiring ZuriMED

(CONNECT) Stryker has signed a definitive agreement to acquire ZuriMED Technologies AG. With ZuriMED's FiberLocker system, the Portage, Michigan-based medtech company is expanding its product portfolio in one of the fastest-growing segments of sports medicine. "ZuriMED has developed an innovative technology that addresses an important clinical need in shoulder treatment," Andy Pierce, Group President of MedSurg and Neurotechnology at Stryker, is quoted as saying in a press release. "We are pleased to add the FiberLocker system to Stryker's product portfolio."

FiberLocker was developed by ZuriMED to improve postoperative healing following rotator cuff reconstruction or augmentation surgery. Founded in 2015 as a spin-off of the University of Zurich and the Swiss Federal Institute of Technology Zurich, and based on the Balgrist Campus, the company has adapted this technology to the felting of textiles. In this process, the fibers of an implant are interwoven directly with the native tissue. Rotator cuff tears are among the most common shoulder injuries. However, traditional repair techniques often fail at the interface between the suture material and the tendon tissue.

FiberLocker received approval in the United States in December 2024. According to the 2025 annual report from Balgrist University Hospital, with which ZuriMED works closely, the clinical market launch was “extremely successful and significantly exceeded expectations.” As early as the year it was launched, the FiberLocker system had been used in nearly 1,000 surgical procedures in the United States and had generated a wealth of clinical data.

Stryker employs approximately 56,000 people worldwide and generated revenue of $25.1 billion in 2025. According to the statement, ZuriMED and Stryker will continue to conduct business as usual until the transaction is finalised. ce/mm